EUVIMEDEUVIMED entdecken
Crossref

Health economic evaluation of a risk-stratified intervention in diabetic kidney disease

Tosha A Kalhan, Miyang Luo, Jia Hui Chai, E Shyong Tai, Su Chi Lim, Thomas M Coffman, Kavita Venkataraman

Diabetologia · 2025

DOI: 10.1007/s00125-025-06498-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetologia, 2025. Verfasst von Tosha A Kalhan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Saw Swee Hock School of Public Health, National University Singapore, Singapore, Republic of Singapore. Hauptthemen laut MEDLINE: Diabetic Nephropathies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Biomedical Research Council, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS/HYPOTHESIS: The study aimed to model the progression of diabetic kidney disease (DKD) in a multi-ethnic Asian population and evaluate the economic impact of a risk-stratified intervention for DKD management. METHODS: Using the Singapore Diabetic Cohort (N=9660), multi-state Markov models were constructed to derive chronic kidney disease (CKD) stage-specific transition probabilities for disease progression based on Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. These were internally validated in 50% training and 50% testing datasets and further validated in national administrative datasets (N=73,256). A cost-effectiveness and budget impact analysis for a hypothetical intervention of sodium-glucose cotransporter 2 inhibitors (SGLT2is) was conducted from a healthcare system perspective, across different time horizons, in low-risk (G0-G2) and high-risk individuals (G3-G4) based on eGFR-defined DKD risk stages. RESULTS: Annually, more than half of the participants (53.0-88.8%) stayed in the same DKD stage, with the probabilities of progressing or regressing to the next DKD stage being highest between stages G0 and G1. The SGLT2i intervention was cost-effective when given in low-risk, but not in high-risk, individuals with type 2 diabetes in both the short and the long term. Additionally, implementing the SGLT2i intervention would incur a 5 year cumulative cost increase of 41.5%, assuming an annual 5% increase in market uptake. CONCLUSIONS/INTERPRETATION: We developed a robust model of DKD progression based on real-world data and demonstrated its value through economic modelling of risk-stratified interventions with known effectiveness. This model can aid policymakers and health professionals in evaluating population-level interventions for evidence-based policy decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesHumansCost-Benefit AnalysisMaleFemaleMiddle AgedSodium-Glucose Transporter 2 InhibitorsDisease ProgressionMarkov ChainsAgedSingaporeDiabetes Mellitus, Type 2AdultGlomerular Filtration RateRenal Insufficiency, Chronic

Stichwörter der Autor:innen

Asian populationBudget impactChronic kidney diseaseCost-effectivenessDiabetic kidney diseaseEconomic evaluationHealth policyMarkov modelRisk stratificationSGLT2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Saw Swee Hock School of Public Health, National University Singapore, Singapore, Republic of Singapore.
  • Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, Hunan, China.
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.
  • Diabetes Centre, Admiralty Medical Centre, Singapore, Republic of Singapore.
  • Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Republic of Singapore.

Förderung

  • Biomedical Research Council
  • National Medical Research Council

Zitieren

APA

Kalhan, T. A., Luo, M., Chai, J. H., Tai, E. S., Lim, S. C., Coffman, T. M., & Venkataraman, K. (2025). Health economic evaluation of a risk-stratified intervention in diabetic kidney disease. Diabetologia. https://doi.org/10.1007/s00125-025-06498-0

Vancouver

Kalhan TA, Luo M, Chai JH, Tai ES, Lim SC, Coffman TM, et al. Health economic evaluation of a risk-stratified intervention in diabetic kidney disease. Diabetologia. 2025. doi:10.1007/s00125-025-06498-0

BibTeX
@article{Kalhan2025,
  author = {Kalhan, Tosha A and Luo, Miyang and Chai, Jia Hui and Tai, E Shyong and Lim, Su Chi and Coffman, Thomas M and Venkataraman, Kavita},
  title = {Health economic evaluation of a risk-stratified intervention in diabetic kidney disease},
  journal = {Diabetologia},
  year = {2025},
  doi = {10.1007/s00125-025-06498-0}
}
Kostenlos starten →